近视与老花眼治疗市场－2026-2031年预测

近视和老花眼治疗市场预计将从 2025 年的 284.34 亿美元增长到 2031 年的 463.07 亿美元，复合年增长率为 8.47%。

近视和老花眼治疗市场涵盖了针对全球两种最常见屈光不正的一系列动态且不断扩展的矫正和治疗方案。近视主要由眼轴长度延长引起，而老花眼则由水晶体调节功能老龄化增加而下降所引起。推动这两个市场共同发展的，是强大的、相互关联的人口结构和生活方式趋势。人口老化、现代生活方式的改变以及持续的技术创新，导致全球近视和老花眼患病率不断上升，从而在外科手术、药物治疗和视力矫正等领域创造了持续的需求。

近视治疗领域的一个重要且强大的驱动因素是全球近视盛行率的不断上升，尤其是在年轻人中，近视的发病年龄越来越早，病情进展也越来越快。这一趋势与都市化相关的生活方式因素密切相关，例如长时间近距离用眼（过度使用电子设备）、户外活动减少以及学业压力。这些环境和行为模式的改变导致越来越多的年轻患者需要接受治疗，这些治疗不仅能矫正屈光，还能延缓近视进展，进而降低长期眼部健康风险。

同时，全球人口老化正直接且不可逆转地推动老花眼治疗领域的发展。老花眼，老龄化，随着40岁以上人口比例的增加，代表着一个巨大且不断增长的潜在市场。这群人通常更注重健康，拥有更大的自由裁量权收入，因此他们寻求的解决方案不仅限于普通的阅读眼镜，还包括先进的光学矫正、手术治疗以及能够恢復功能性近视力并支持积极生活方式的新兴药物疗法。

技术进步是推动整个市场发展的关键促进者。在外科矫正领域，创新技术不断提升治疗效果。在近视矫正方面，波前导引和角膜地形图导引的雷射手术（LASIK、PRK、SMILE）提高了手术的精确度和个人化程度。在老花眼矫正方面，进展包括景深扩展型和多焦点人工水晶体（IOL）、角膜嵌体以及基于雷射的老花眼矫正技术。除了手术之外，老花眼的药物治疗领域也正在进行大量的研发工作，新型眼药水正在研究透过调节瞳孔大小和景深来暂时改善近距离力，这预示着老花眼治疗模式转移。

除了技术进步之外，公众和专业人士的意识提升也发挥关键作用。医疗机构、专业协会和产业相关人员的教育努力，正推动人们日益认识到，眼部疾病和眼睑疾病都是可治疗的健康问题，而非无法避免的不便。这种意识的提高促进了早期诊断，鼓励患者与眼科医生讨论各种治疗方案，并增加了患者对针对特定生活方式的个人化治疗方法的需求，所有这些都在推动市场成长和发展。

从区域来看，北美仍然是领先且成熟的市场。屈光不正的高发生率、完善的先进眼科中心体系、较高的患者意识以及许多手术项目有利的报销机制，都巩固了北美市场的地位。此外，该地区还聚集了许多大型医疗设备和製药公司，促进了创新技术的快速引进週期，并使其成为临床研究和开发的重要中心。

儘管成长要素强劲，但市场仍面临许多限制因素，影响眼科医疗服务的可近性和普及率。其中一个主要障碍是许多先进治疗方案，特别是选择性屈光矫正手术和高端人工水晶体（IOL）的高昂自付费用，这些费用可能无法完全由保险覆盖。这种对价格的敏感度会限制治疗的普及，尤其是在价格敏感人群中。此外，患者对手术和新型药物的安全性、有效性和潜在副作用的担忧也会造成犹豫，因此需要医疗专业人员进行充分的咨询和建立信任。获得专业眼科护理服务和先进诊断技术的途径仍然不均衡，尤其是在农村和医疗服务不足的地区，造成了治疗缺口。

眼科器材产业的竞争格局由大规模眼科器材公司、专业製药公司和光学产品製造商组成。领先企业凭藉在雷射平台和人工水晶体设计方面的技术优势、可靠的临床数据支持其安全性和有效性，以及为眼科专业人员提供的全面服务和培训支援展开竞争。其策略重点领域包括：开发延缓近视进展的联合疗法；研发可减少闪光感的下一代人工水晶体矫正型人工水晶体；以及将首个获得FDA核准的老花眼药物推向市场。

总之，近视和老花眼治疗市场正从简单的屈光矫正更全面的模式发展，涵盖缓解疾病、功能恢復和个人化管理。人口结构和生活方式的必然变化推动了全球患者群体的扩大，从而为其成长提供了结构性支撑。未来市场发展将取决于新型药物的成功商业化、手术效果和患者体验的持续改善，以及提高先进疗法的成本效益和可及性的努力。这些因素共同作用，使市场能够持续创新和扩张，以满足日益增长且老化的全球人口的视觉需求。

本报告的主要优势：

• 深入分析：提供对主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、行业垂直领域和其他细分市场。
• 竞争格局：了解全球主要参与者的策略倡议，并了解透过正确的策略进入市场的机会。
• 市场驱动因素与未来趋势：探讨影响市场的动态因素和关键趋势及其对未来市场发展的影响。
• 可操作的建议：利用这些见解，在动态环境中做出策略决策，并开拓新的商机和收入来源。
• 受众广泛：适用于Start-Ups、研究机构、顾问公司、中小企业和大型企业，且经济实惠。

您打算如何使用这份报告？

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

报告范围：

• 2021年至2025年的历史数据和2026年至2031年的预测数据
• 成长机会、挑战、供应链前景、法规结构与趋势分析
• 竞争定位、策略和市场占有率分析
• 按业务板块和地区（包括国家）分類的收入和预测评估
• 公司概况（策略、产品、财务资讯、关键发展等）

目录

第一章执行摘要

第二章 市场概览

• 市场概览
• 市场定义
• 调查范围
• 市场区隔

第三章 商业情境

• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析
• 产业价值链分析
• 政策与法规
• 策略建议

第四章 技术展望

第五章 依疾病类型分類的近视与老花眼治疗市场

• 介绍
• 近视
• 老花眼

第六章 近视和老花眼治疗市场（依治疗方法划分）

• 介绍
• 处方镜片
• 隐形眼镜
• 外科手术
• 药物治疗

第七章 按最终使用者分類的近视和老花眼治疗市场

• 介绍
• 医院
• 眼科诊所
• 其他的

第八章：各地区近视与老花眼治疗市场

• 介绍
• 北美洲
  • 依疾病类型
  • 透过治疗方法
  • 最终用户
  • 按国家/地区
    • 我们
    • 加拿大
    • 墨西哥
• 南美洲
  • 依疾病类型
  • 透过治疗方法
  • 最终用户
  • 按国家/地区
    • 巴西
    • 阿根廷
    • 其他的
• 欧洲
  • 依疾病类型
  • 透过治疗方法
  • 最终用户
  • 按国家/地区
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他的
• 中东和非洲
  • 依疾病类型
  • 透过治疗方法
  • 最终用户
  • 按国家/地区
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
• 亚太地区
  • 依疾病类型
  • 透过治疗方法
  • 最终用户
  • 按国家/地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 台湾
    • 其他的

第九章 竞争格局与分析

• 主要企业和策略分析
• 市占率分析
• 合併、收购、协议和合作
• 竞争对手仪錶板

第十章：公司简介

• Ziemer Ophthalmic Systems AG
• ALCON Inc.
• Bausch Health Companies Inc.
• Essilor Ltd
• Johnson & Johnson
• NIDEK CO. LTD
• Topcon Corporation
• Carl Zeiss
• AbbVie
• Cooper Companies Inc

第十一章附录

• 货币
• 先决条件
• 基准年和预测年时间表
• 相关人员的主要收益
• 调查方法
• 简称

Myopia And Presbyopia Treatment Market is forecasted to rise at a 8.47% CAGR, reaching USD 46.307 billion in 2031 from USD 28.434 billion in 2025.

The myopia and presbyopia treatment market encompasses a dynamic and expanding spectrum of corrective and therapeutic solutions for two of the most prevalent refractive errors globally. While distinct in their etiology-myopia primarily driven by axial elongation and presbyopia by age-related loss of lens accommodation-their combined market is propelled by powerful, interconnected demographic and lifestyle trends. The growing global prevalence of both conditions, fueled by an aging population and modern behavioral shifts, alongside continuous technological innovation, is creating sustained demand across surgical, pharmacological, and optical correction segments.

A fundamental and potent driver for the myopia treatment segment is the rising global prevalence of myopia, particularly its early onset and progression in younger populations. This trend is strongly correlated with lifestyle factors associated with urbanization, including increased engagement in prolonged near-work activities (extensive digital device usage), reduced time spent outdoors, and educational pressures. The shift towards these environmental and behavioral patterns is creating a larger and younger patient pool requiring intervention, not only for refractive correction but increasingly for treatments aimed at slowing myopic progression itself to mitigate long-term ocular health risks.

Concurrently, the presbyopia treatment segment is being directly and irreversibly driven by global demographic aging. As a natural, age-related condition affecting near vision, the increasing proportion of the population over the age of 40 represents a vast and expanding addressable market. This demographic is typically more health-aware and possesses greater discretionary spending power, seeking solutions that extend beyond basic reading glasses to more advanced optical corrections, surgical options, and emerging pharmacological therapies that restore functional near vision and support an active lifestyle.

Technological advancement serves as a critical catalyst across the entire market. In surgical correction, innovations continue to refine outcomes. For myopia, wavefront-guided and topography-guided laser procedures (LASIK, PRK, SMILE) enhance precision and customization. For presbyopia, advancements include extended depth-of-focus and multifocal intraocular lenses (IOLs), corneal inlays, and laser-based presbyopia correction techniques. Beyond surgery, significant research and development is focused on pharmacological treatments for presbyopia, investigating novel topical agents designed to temporarily improve near vision by modulating pupil size or depth of focus, representing a potential paradigm shift towards non-invasive management.

Parallel to technological progress is the role of increasing public and professional awareness. Educational campaigns by healthcare organizations, professional societies, and industry participants are elevating the understanding of both conditions as treatable health issues rather than inevitable inconveniences. This heightened awareness is encouraging earlier diagnosis, discussion of a broader range of treatment options with eye care professionals, and greater patient demand for interventions that align with specific lifestyle needs, thereby driving market growth and sophistication.

Geographically, North America remains a dominant and mature market. This position is reinforced by a high prevalence of refractive errors, a well-established infrastructure of advanced ophthalmic care centers, high patient awareness, and favorable reimbursement frameworks for many surgical procedures. The region's concentration of leading medical device and pharmaceutical companies also fosters a rapid adoption cycle for innovative technologies and serves as a primary hub for clinical research and development.

Despite strong growth drivers, the market faces several restraints that impact accessibility and adoption. A significant barrier is the high out-of-pocket cost associated with many advanced treatments, particularly elective refractive surgeries and premium IOLs, which may not be fully covered by insurance plans. This cost sensitivity can limit uptake, especially in price-conscious segments. Furthermore, concerns regarding the safety, efficacy, and potential side effects of surgical procedures or novel pharmacological agents can create patient hesitancy, necessitating extensive counseling and trust-building by practitioners. Access to specialized eye care services and advanced diagnostic technology also remains uneven, particularly in rural and underserved regions globally, creating disparities in treatment availability.

The competitive landscape is characterized by a mix of large, diversified ophthalmic device companies, specialized pharmaceutical firms, and optical product manufacturers. Key players compete on the basis of technological leadership in laser platforms and IOL design, robust clinical data supporting safety and efficacy, and comprehensive service and training support for eye care professionals. Strategic focus areas include developing combination therapies for myopia control, next-generation presbyopia-correcting IOLs with reduced dysphotopsias, and bringing the first wave of FDA-approved pharmacological presbyopia treatments to market.

In conclusion, the myopia and presbyopia treatment market is evolving from a focus solely on refractive correction towards a more holistic model encompassing disease modification, functional restoration, and personalized management. Its growth is structurally supported by inescapable demographic and lifestyle trends that are expanding the global patient base. Future market development will be shaped by the successful commercialization of novel pharmacological agents, continued refinement of surgical outcomes and patient experience, and efforts to improve the cost-effectiveness and accessibility of advanced treatments. The convergence of these factors positions the market for ongoing innovation and expansion as it addresses the visual needs of a growing and aging global population.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Myopia and Presbyopia Treatment Market Segmentation

• By Disease Type
• Myopia
• Presbyopia
• By Treatment Type
• Prescription Lenses
• Contact Lenses
• Surgery
• Medication
• By End-User
• Hospitals
• Eyecare Centers & Clinics
• Others
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Taiwan
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. MYOPIA AND PRESBYOPIA TREATMENT MARKET BY DISEASE TYPE

• 5.1. Introduction
• 5.2. Myopia
• 5.3. Presbyopia

6. MYOPIA AND PRESBYOPIA TREATMENT MARKET BY TREATMENT TYPE

• 6.1. Introduction
• 6.2. Prescription Lenses
• 6.3. Contact Lenses
• 6.4. Surgery
• 6.5. Medication

7. MYOPIA AND PRESBYOPIA TREATMENT MARKET BY END-USER

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Eyecare Centers & Clinics
• 7.4. Others

8. MYOPIA AND PRESBYOPIA TREATMENT MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. By Disease Type
  • 8.2.2. By Treatment Type
  • 8.2.3. By End-User
  • 8.2.4. By Country
    • 8.2.4.1. USA
    • 8.2.4.2. Canada
    • 8.2.4.3. Mexico
• 8.3. South America
  • 8.3.1. By Disease Type
  • 8.3.2. By Treatment Type
  • 8.3.3. By End-User
  • 8.3.4. By Country
    • 8.3.4.1. Brazil
    • 8.3.4.2. Argentina
    • 8.3.4.3. Others
• 8.4. Europe
  • 8.4.1. By Disease Type
  • 8.4.2. By Treatment Type
  • 8.4.3. By End-User
  • 8.4.4. By Country
    • 8.4.4.1. Germany
    • 8.4.4.2. France
    • 8.4.4.3. United Kingdom
    • 8.4.4.4. Spain
    • 8.4.4.5. Italy
    • 8.4.4.6. Others
• 8.5. Middle East and Africa
  • 8.5.1. By Disease Type
  • 8.5.2. By Treatment Type
  • 8.5.3. By End-User
  • 8.5.4. By Country
    • 8.5.4.1. Saudi Arabia
    • 8.5.4.2. UAE
    • 8.5.4.3. Others
• 8.6. Asia Pacific
  • 8.6.1. By Disease Type
  • 8.6.2. By Treatment Type
  • 8.6.3. By End-User
  • 8.6.4. By Country
    • 8.6.4.1. China
    • 8.6.4.2. India
    • 8.6.4.3. Japan
    • 8.6.4.4. South Korea
    • 8.6.4.5. Indonesia
    • 8.6.4.6. Thailand
    • 8.6.4.7. Taiwan
    • 8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Ziemer Ophthalmic Systems AG
• 10.2. ALCON Inc.
• 10.3. Bausch Health Companies Inc.
• 10.4. Essilor Ltd
• 10.5. Johnson & Johnson
• 10.6. NIDEK CO. LTD
• 10.7. Topcon Corporation
• 10.8. Carl Zeiss
• 10.9. AbbVie
• 10.10. Cooper Companies Inc

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations